Perrigo ROA 2012-2026 | PRGO
Current and historical return on assets (ROA) values for Perrigo (PRGO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Perrigo ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-06-30 | $-1.73B | $8.55B | -20.27% |
| 2026-03-31 | $-1.82B | $9.17B | -19.81% |
| 2025-12-31 | $-1.42B | $9.62B | -14.81% |
| 2025-09-30 | $-0.05B | $9.90B | -0.51% |
| 2025-06-30 | $-0.08B | $10.18B | -0.78% |
| 2025-03-31 | $-0.18B | $10.25B | -1.75% |
| 2024-12-31 | $-0.17B | $10.47B | -1.63% |
| 2024-09-30 | $-0.16B | $10.76B | -1.48% |
| 2024-06-30 | $-0.12B | $10.65B | -1.16% |
| 2024-03-31 | $-0.01B | $10.79B | -0.07% |
| 2023-12-31 | $-0.01B | $10.87B | -0.12% |
| 2023-09-30 | $-0.01B | $10.92B | -0.05% |
| 2023-06-30 | $-0.07B | $10.90B | -0.62% |
| 2023-03-31 | $-0.14B | $10.89B | -1.29% |
| 2022-12-31 | $-0.14B | $10.75B | -1.30% |
| 2022-09-30 | $-0.11B | $10.60B | -1.00% |
| 2022-06-30 | $-0.12B | $10.66B | -1.09% |
| 2022-03-31 | $-0.11B | $10.74B | -1.01% |
| 2021-12-31 | $-0.07B | $10.97B | -0.63% |
| 2021-09-30 | $-0.25B | $11.24B | -2.26% |
| 2021-06-30 | $-0.35B | $11.41B | -3.07% |
| 2021-03-31 | $-0.23B | $11.63B | -1.99% |
| 2020-12-31 | $-0.16B | $11.65B | -1.40% |
| 2020-09-30 | $-0.01B | $11.60B | -0.06% |
| 2020-06-30 | $0.24B | $11.54B | 2.08% |
| 2020-03-31 | $0.19B | $11.36B | 1.65% |
| 2019-12-31 | $0.15B | $11.29B | 1.29% |
| 2019-09-30 | $0.25B | $11.21B | 2.20% |
| 2019-06-30 | $0.09B | $11.12B | 0.78% |
| 2019-03-31 | $0.11B | $11.07B | 1.03% |
| 2018-12-31 | $0.13B | $11.20B | 1.17% |
| 2018-09-30 | $0.12B | $11.36B | 1.07% |
| 2018-06-30 | $0.24B | $11.59B | 2.03% |
| 2018-03-31 | $0.13B | $11.73B | 1.10% |
| 2017-12-31 | $0.12B | $12.31B | 0.97% |
| 2017-09-30 | $-1.31B | $12.87B | -10.19% |
| 2017-06-30 | $-2.95B | $13.88B | -21.23% |
| 2017-03-31 | $-3.41B | $15.51B | -22.00% |
| 2016-12-31 | $-4.01B | $16.89B | -23.76% |
| 2016-09-30 | $-2.83B | $18.26B | -15.48% |
| 2016-06-30 | $-0.98B | $19.21B | -5.08% |
| 2016-03-31 | $-0.46B | $19.57B | -2.37% |
| 2015-12-31 | $0.04B | $18.74B | 0.23% |
| 2015-09-30 | $0.29B | $18.02B | 1.59% |
| 2015-06-30 | $0.12B | $16.54B | 0.74% |
| 2014-12-31 | $0.21B | $14.47B | 1.48% |
| 2014-09-30 | $0.06B | $13.78B | 0.42% |
| 2013-12-31 | $0.14B | $7.27B | 1.89% |
| 2013-09-30 | $0.33B | $4.91B | 6.70% |
| 2012-12-31 | $0.33B | $4.12B | 7.96% |
| 2012-09-30 | $0.32B | $4.03B | 7.99% |
| 2011-12-31 | $0.26B | $3.42B | 7.57% |
| 2011-09-30 | $0.25B | $3.17B | 7.86% |
| 2010-12-31 | $0.23B | $2.83B | 8.00% |
| 2010-09-30 | $0.20B | $2.71B | 7.28% |
| 2009-12-31 | $0.16B | $2.44B | 6.51% |
| 2009-09-30 | $0.12B | $2.44B | 5.05% |
| 2008-12-31 | $0.10B | $2.43B | 4.24% |
| 2008-09-30 | $0.11B | $2.33B | 4.80% |
| 2007-12-31 | $0.09B | $1.95B | 4.36% |
| 2007-09-30 | $0.07B | $1.90B | 3.78% |
| 2006-12-31 | $0.06B | $1.77B | 3.33% |
| 2006-09-30 | $0.06B | $1.73B | 3.64% |
| 2005-12-31 | $-0.34B | $1.70B | -20.03% |
| 2005-09-30 | $-0.35B | $1.48B | -23.68% |
| 2004-12-31 | $0.05B | $0.76B | 6.81% |
| 2004-09-30 | $0.07B | $0.74B | 9.95% |
| 2003-12-31 | $0.07B | $0.66B | 10.47% |
| 2003-09-30 | $0.05B | $0.64B | 7.55% |
| 2002-12-31 | $0.05B | $0.60B | 9.06% |
| 2002-09-30 | $0.05B | $0.59B | 8.89% |
| 2001-12-31 | $0.04B | $0.57B | 6.65% |
| 2001-09-30 | $0.02B | $0.56B | 4.29% |
| 2001-03-31 | $0.01B | $0.52B | 2.71% |
| 2000-12-31 | $0.01B | $0.51B | 1.97% |
| 2000-09-30 | $0.02B | $0.52B | 3.82% |
| 2000-06-30 | $0.02B | $0.55B | 3.48% |
| 2000-03-31 | $0.02B | $0.58B | 4.15% |
| 1999-12-31 | $0.03B | $0.62B | 4.49% |
| 1999-09-30 | $0.02B | $0.66B | 3.66% |
| 1999-06-30 | $0.00B | $0.66B | 0.30% |
| 1999-03-31 | $-0.08B | $0.66B | -12.80% |
| 1998-12-31 | $-0.09B | $0.65B | -13.13% |
| 1998-09-30 | $-0.08B | $0.63B | -12.38% |
| 1998-06-30 | $-0.05B | $0.63B | -8.45% |
| 1998-03-31 | $0.05B | $0.62B | 7.26% |
| 1997-12-31 | $0.05B | $0.60B | 8.02% |
| 1997-09-30 | $0.05B | $0.58B | 8.29% |
| 1997-06-30 | $0.05B | $0.57B | 8.12% |
| 1997-03-31 | $0.04B | $0.56B | 7.47% |
| 1996-12-31 | $0.04B | $0.56B | 7.29% |
| 1996-09-30 | $0.04B | $0.57B | 6.84% |
| 1996-06-30 | $0.04B | $0.58B | 6.95% |
| 1996-03-31 | $0.04B | $0.58B | 6.93% |
| 1995-12-31 | $0.04B | $0.57B | 6.97% |
| 1995-09-30 | $0.04B | $0.55B | 7.43% |
| 1995-06-30 | $0.04B | $0.53B | 8.30% |
| 1995-03-31 | $0.05B | $0.51B | 10.00% |
| 1994-12-31 | $0.05B | $0.49B | 10.86% |
| 1994-09-30 | $0.06B | $0.48B | 11.57% |
| 1994-06-30 | $0.06B | $0.46B | 11.89% |
| 1994-03-31 | $0.05B | $0.45B | 12.07% |
| 1993-12-31 | $0.05B | $0.43B | 12.12% |
| 1993-09-30 | $0.05B | $0.41B | 12.03% |
| 1993-06-30 | $0.04B | $0.38B | 11.59% |
| 1993-03-31 | $0.04B | $0.36B | 11.53% |
| 1992-12-31 | $0.04B | $0.33B | 11.43% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $1.894B | $4.253B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $178.385B | 19.60 |
| Medtronic (MDT) | Ireland | $119.983B | 16.40 |
| Stryker (SYK) | United States | $108.118B | 20.21 |
| EssilorLuxottica (ESLOY) | France | $79.433B | 0.00 |
| Boston Scientific (BSX) | United States | $65.288B | 14.03 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.930B | 0.00 |
| Medline (MDLN) | United States | $42.846B | 0.00 |
| Agilent Technologies (A) | United States | $41.387B | 24.22 |
| ResMed (RMD) | United States | $32.167B | 19.96 |
| GE HealthCare Technologies (GEHC) | United States | $29.021B | 13.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.651B | 13.13 |
| Terumo (TRUMY) | Japan | $21.625B | 20.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.414B | 11.38 |
| Baxter (BAX) | United States | $12.336B | 11.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.926B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.854B | 39.71 |
| Demant (WILYY) | Denmark | $9.592B | 0.00 |
| Insulet (PODD) | United States | $9.557B | 23.48 |
| Sunny Optical Technology (SNPTF) | China | $9.142B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.548B | 20.15 |
| Raia Drogasil SA - (RADLY) | $4.931B | 0.00 | |
| Haemonetics (HAE) | United States | $4.837B | 21.22 |
| BillionToOne (BLLN) | United States | $4.757B | 144.03 |
| DiaSorin S.p.A (DSRLF) | Italy | $4.705B | 0.00 |
| Envista Holdings (NVST) | United States | $4.142B | 17.54 |
| ICU Medical (ICUI) | United States | $3.939B | 23.52 |
| AtriCure (ATRC) | United States | $2.838B | 242.57 |
| Neogen (NEOG) | United States | $2.606B | 45.96 |
| Curaleaf Holdings (CURLD) | Canada | $2.388B | 0.00 |
| Curaleaf Holdings (CURLF) | United States | $2.356B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.256B | 10.77 |
| Trulieve Cannabis (TRLV) | United States | $2.238B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.207B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.847B | 29.69 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $1.798B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.736B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.733B | 221.44 |
| Phibro Animal Health (PAHC) | United States | $1.459B | 11.20 |
| Green Thumb Industries (GTBIF) | United States | $1.428B | 15.23 |
| Kestra Medical Technologies (KMTS) | United States | $1.410B | 0.00 |
| Omeros (OMER) | United States | $1.264B | 6.40 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.094B | 0.00 |
| CeriBell (CBLL) | United States | $0.934B | 0.00 |
| InMode (INMD) | Israel | $0.856B | 11.91 |
| AdaptHealth (AHCO) | United States | $0.802B | 16.80 |
| VAREX IMAGING (VREX) | United States | $0.777B | 17.09 |
| QuidelOrtho (QDEL) | United States | $0.763B | 8.24 |
| Glass House Brands (GLAS) | United States | $0.760B | 0.00 |
| Valneva SE (VALN) | France | $0.633B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.582B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.564B | 0.00 |
| Brainsway (BWAY) | Israel | $0.548B | 30.98 |
| Evolus (EOLS) | United States | $0.524B | 0.00 |
| Cerus (CERS) | United States | $0.514B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.512B | 0.00 |
| Vireo Growth (VREOD) | United States | $0.451B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.438B | 0.00 |
| Verano Holdings (VRNOD) | United States | $0.425B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.422B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.395B | 8.28 |
| Cresco Labs (CRLBF) | United States | $0.373B | 0.00 |
| SNDL (SNDL) | Canada | $0.353B | 0.00 |
| Village Farms (VFF) | Canada | $0.347B | 15.78 |
| Viemed Healthcare (VMD) | United States | $0.337B | 24.56 |
| Sanara MedTech (SMTI) | United States | $0.321B | 159.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.294B | 0.00 |
| MacroGenics (MGNX) | United States | $0.268B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 13.14 |
| High Tide (HITI) | Canada | $0.234B | 52.60 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.225B | 21.55 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.194B | 0.00 |
| Exagen (XGN) | United States | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Jin Medical (ZJYL) | China | $0.155B | 0.00 |
| Organigram Global (OGI) | Canada | $0.152B | 0.00 |
| Apyx Medical (APYX) | United States | $0.127B | 0.00 |
| Quanterix (QTRX) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| ImmuCell (ICCC) | United States | $0.088B | 121.38 |
| Accendra Health (ACH) | United States | $0.086B | 4.87 |
| FitLife Brands (FTLF) | United States | $0.086B | 11.30 |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| InterCure (INCR) | Israel | $0.058B | 0.00 |
| Hongchang (HCIL) | China | $0.052B | 0.00 |
| Biote (BTMD) | United States | $0.050B | 4.12 |
| Nephros (NEPH) | United States | $0.048B | 40.27 |
| Veru (VERU) | United States | $0.040B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.037B | 17.71 |
| United-Guardian (UG) | United States | $0.033B | 13.26 |
| Rockwell Medical (RMTI) | United States | $0.031B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.022B | 0.00 |
| Modular Medical (MODD) | United States | $0.021B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.019B | 0.00 |
| Bonk (BNKK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.000B | 0.00 |
| INLIF (INLF) | China | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |